What the Pediatric Research Equity Act requires

The Pediatric Research Equity Act treats pediatric data as the default expectation for a new drug or biologic, not a courtesy you add once the adult program is finished. If an application triggers PREA, FDA expects a plan for assessing the product in pediatric patients unless that plan is formally deferred or waived — and neither of those is something you ask for after the fact.

The trigger is about the application, not the disease

PREA doesn’t ask whether a disease affects children. It asks whether the specific application in front of FDA — a new active ingredient, a new indication, a new dosage form, a new dosing regimen, or a new route of administration — falls within a category the statute covers. A supplement for a new indication on an already-approved drug can trigger PREA on its own, even if the original approval predated the statute or never raised a pediatric question at all. Figuring out whether a given submission trips that wire is a question worth asking the moment the regulatory strategy for that submission takes shape, not after the application is drafted.

Deferral buys time; it doesn’t buy out

A deferral is the mechanism most sponsors actually use, and it’s easy to mistake for a waiver because the practical effect — adult approval without pediatric data in hand yet — looks similar at the moment of approval. It isn’t the same commitment. A deferral requires certifying the grounds for it, submitting a pediatric study plan, showing due diligence toward starting and completing the studies, and reporting progress annually, publicly, until the assessments are done. Treating a deferral as a problem solved rather than a program still open is the same mistake as treating any open regulatory commitment as finished the day it’s granted instead of tracked until it’s actually closed out.

Waivers are not “we’d rather not”

A full waiver requires FDA to find that pediatric studies are impossible or highly impracticable, that there’s evidence strongly suggesting the product would be ineffective or unsafe in all pediatric age groups, or that the product doesn’t represent a meaningful therapeutic benefit over existing therapies for pediatric patients and isn’t likely to be used by a substantial number of them. None of those findings turn on cost, timeline pressure, or a sponsor’s preference to focus resources on the adult indication first — which is exactly the gap a deferral exists to cover instead.

None of this is a reason to treat PREA as an obstacle to route around. It’s a planning input, like any other regulatory requirement with a real lead time attached to it — and the sponsors who handle it best are the ones who raise it at the same pre-submission meeting where the rest of the development plan gets shaped, not the ones who discover it while assembling the application.